BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2026 9:45:09 AM | Browse: 1 | Download: 1
 |
Received |
|
2026-01-30 01:02 |
|
Peer-Review Started |
|
2026-01-30 01:02 |
|
First Decision by Editorial Office Director |
|
2026-02-12 08:00 |
|
Return for Revision |
|
2026-02-12 08:00 |
|
Revised |
|
2026-02-12 12:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-05-07 03:24 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-07 11:49 |
|
Articles in Press |
|
2026-05-07 11:49 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-08 06:58 |
|
Publish the Manuscript Online |
|
2026-09-09 09:45 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the editor: Role of adjuvant programmed death-1 blockade combined with chemotherapy in resected pancreatic ductal adenocarcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jin-Wei Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82170406 and No. 81970238 |
|
| Corresponding Author |
Jin-Wei Zhang, PhD, Principal Investigator, Professor, tate Key Laboratory of Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No. 345 Lingling Road, Shanghai 200032, China. jinweizhang@sioc.ac.cn |
| Key Words |
Pancreatic ductal adenocarcinoma; Adjuvant therapy; Programmed death-1 inhibitor; Immunotherapy; Recurrence-free survival; Real-world evidence |
| Core Tip |
Although immune checkpoint inhibitors have shown minimal efficacy in advanced pancreatic cancer, the postoperative adjuvant setting may offer a biologically favorable window for immune intervention. A recent study suggested that combining programmed death-1 inhibition with chemotherapy after surgical resection may improve recurrence-related outcomes without excessive toxicity, providing a compelling rationale for prospective, biomarker-informed trials in this historically refractory disease. |
| Publish Date |
2026-09-09 09:45 |
| Citation |
Zhang JW. Letter to the editor: Role of adjuvant programmed death-1 blockade combined with chemotherapy in resected pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2026; 18(9): 119518
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i9/119518.htm |
| DOI |
https://doi.org/10.4251/wjgo.119518 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
